Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1107421/000119312519259378/d809500d8k.htm
January 2022
January 2022
November 2021
October 2021
September 2021
August 2021
August 2021
August 2021
May 2021
May 2021
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1107421/000119312519259378/d809500d8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Ziopharm Oncology Inc.
Ziopharm Oncology Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Ziopharm Oncology Inc provided additional information to their SEC Filing as exhibits
Ticker: ZIOPEvents:
CIK: 1107421
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-259378
Submitted to the SEC: Tue Oct 01 2019 8:43:06 AM EST
Accepted by the SEC: Tue Oct 01 2019
Period: Tuesday, October 1, 2019
Industry: Pharmaceutical Preparations